1-4 of 4
Carol Bivins, Rn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I-II Study of Sequential Therapy with Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Nitin Jain, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Tapan Kadia, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD, Marina Konopleva, MD PhD, Allison Pike, RN, Carol Bivins, RN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2014) 124 (21): 5283.
https://doi.org/10.1182/blood.V124.21.5283.5283
Published: 2014
Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD
Journal: Blood
Blood (2012) 120 (21): 3625.
https://doi.org/10.1182/blood.V120.21.3625.3625
Published: 2012
Journal Articles

High Prevalence of FLT3 - ITD Mutations in Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Central Nervous System (CNS) Relapse.

Fabio P S Santos, MD, Hagop Kantarjian, MD, Tapan Kadia, MD, Carol Bivins, RN, Susan Obrien, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Sherry Pierce, RN, Elias Jabbour, MD
Journal: Blood
Blood (2009) 114 (22): 1020.
https://doi.org/10.1182/blood.V114.22.1020.1020
Published: 2009
Journal Articles

Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study.

Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Solly George, Rn, Carol Bivins, Rn, Jorge Cortes-Franco, MD, William M Garrett, MBA, Robert C Newton, PhD, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 631.
https://doi.org/10.1182/blood.V114.22.631.631
Published: 2009